Document is current
Any future updates will be listed below
-
Authors
Chang, Christopher R. https://orcid.org/0000-0003-3124-8773
Vykunta, Vivasvan S. https://orcid.org/0000-0002-5409-8635
Lee, Jae Hyun J. https://orcid.org/0009-0009-2998-5249
Li, Ke
Kochendoerfer, Clara
Muldoon, Joseph J. https://orcid.org/0000-0003-3784-3565
Wang, Charlotte H.
Mazumder, Thomas
Sun, Yang https://orcid.org/0000-0002-9344-8060
Goodman, Daniel B. https://orcid.org/0000-0003-3759-6883
Nyberg, William A. https://orcid.org/0000-0002-9982-1305
Liu, Chang https://orcid.org/0009-0003-1294-9686
Allain, Vincent
Rothrock, Allison https://orcid.org/0009-0002-6734-6180
Ye, Chun J. https://orcid.org/0000-0001-6560-3783
Marson, Alexander https://orcid.org/0000-0002-2734-5776
Shy, Brian R. https://orcid.org/0000-0001-9569-3708
Eyquem, Justin https://orcid.org/0000-0001-8262-1190
-
Funding
Funding for this research was provided by:
U.S. Department of Health & Human Services | NIH | National Institute of General Medical Sciences (T32GM141323, T32GM141323, K08CA273529, L30TR002983)
UCSF Grand Multiple Myeloma Translational Initiative (MMTI); Achievement Rewards for College Scientists (ARCS) Scholarship
Cancer Research Institute (Irvington postdoctoral fellowship)
UCSF Living Therapeutics Initiative;CRISPR Cures for Cancer Initiative.
- License Information
-
More Information
Article History
Received: 19 December 2023
Accepted: 10 December 2024
First Online: 5 February 2025
Competing interests
: C.R.C., V.S.V., A.M., B.S. and J.E. are inventors on patent filings related to this work. J.E. was a compensated cofounder at Mnemo Therapeutics. J.E. owns stocks in Mnemo Therapeutics and Cytovia Therapeutics. J.E. has received consulting fees from Casdin Capital, Resolution Therapeutics, Cytovia Therapeutics and Treefrog Therapeutics. The J.E. lab has received research support from Cytovia Therapeutics, Mnemo Therapeutics and Takeda Pharmaceutical Company. C.J.Y. has received research support from the Chan Zuckerberg Initiative, Chan Zuckerberg Biohub, Arc Institute, Parker Institute for Cancer Immunotherapy, Genentech, BioLegend, ScaleBio and Illumina. A.M. is a cofounder of Site Tx, Arsenal Biosciences, Spotlight Therapeutics and Survey Genomics, serves on the boards of directors at Site Tx, Spotlight Therapeutics and Survey Genomics, is a member of the scientific advisory boards of Site Tx, Arsenal Biosciences, Cellanome, Spotlight Therapeutics, Survey Genomics, NewLimit, Amgen and Tenaya, owns stock in Arsenal Biosciences, Site Tx, Cellanome, Spotlight Therapeutics, NewLimit, Survey Genomics, Tenaya and Lightcast and has received fees from Site Tx, Arsenal Biosciences, Cellanome, Spotlight Therapeutics, NewLimit, Gilead, Pfizer, 23andMe, PACT Pharma, Juno Therapeutics, Tenaya, Lightcast, Trizell, Vertex, Merck, Amgen, Genentech, GLG, ClearView Healthcare, AlphaSights, Rupert Case Management, Bernstein and ALDA. A.M. is an investor in and informal advisor to Offline Ventures and a client of EPIQ. The A.M. laboratory has received research support from the Parker Institute for Cancer Immunotherapy, the Emerson Collective, Arc Institute, Juno Therapeutics, Epinomics, Sanofi, GlaxoSmithKline, Gilead and Anthem and reagents from Genscript and Illumina. The other authors declare no competing interests.
